Abeona Therapeutics Inc vs Hyatt Hotels Corporation — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Hyatt Hotels Corporation trades at $172.22 (market cap $16.27B). The key difference: Hyatt Hotels Corporation is far larger — about 38.6× Abeona Therapeutics Inc's market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | H | |
|---|---|---|
Market Cap | $421.19M | $16.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $202.09 |
52-Week Low | $4.17 | $135.42 |
Enterprise Value | $276.10M | $20.17B |
Dividend Yield | — | 0.35% |
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →